OrbiMed Portfolio holdings
OrbiMed is an investment manager focused exclusively on healthcare, running public equity, private equity and private credit and royalty funds. The firm traces its origins to 1989, when Viren Mehta and Samuel Isaly, both pharmaceutical analysts at the bank S.G Warburg, set up the research and money-management firm Mehta & Isaly; in 1998 it split in two, with Isaly forming OrbiMed and Mehta forming Mehta Partners. Its public equity side covers long/short funds built around corporate events as well as closed-end investment trusts, and OrbiMed launched its first dedicated venture capital fund in 2000 and its first royalty and credit fund in 2011. Carl Gordon, Carter Neild and Geoffrey Hsu form the committee that leads the firm, which is owned and controlled by eight members.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Integer Holdings
ITGR
|
+$40.8M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$39.5M |
| 3 |
Exact Sciences
EXAS
|
+$29.3M |
| 4 |
argenx
ARGX
|
+$22M |
| 5 |
Amgen
AMGN
|
+$21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alpine Immune Sciences Inc
ALPN
|
+$106M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$104M |
| 3 |
Janux Therapeutics
JANX
|
+$60.8M |
| 4 |
Esperion Therapeutics
ESPR
|
+$36.7M |
| 5 |
Scholar Rock
SRRK
|
+$30.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.69% |
| 2 | Miscellaneous | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
| $340M | 6.71% |
2,718,735
| – | – |
2022 Q2
8 quarters
|
|
2
Eli Lilly
LLY
$1.26T
| $306M | 6.04% |
337,600
-23,200
| -6% | -$18.6M |
2023 Q1
5 quarters
|
|
3
Edgewise Therapeutics
EWTX
$4.16B
| $271M | 5.34% |
15,021,721
| – | – |
2021 Q1
13 quarters
|
|
4
Boston Scientific
BSX
$60.9B
| $252M | 4.98% |
3,273,000
| – | – |
2014 Q1
41 quarters
|
|
5
Intuitive Surgical
ISRG
$153B
| $219M | 4.33% |
493,100
| – | – |
2013 Q4
42 quarters
|
|
6
Biogen
BIIB
$37.3B
| $209M | 4.12% |
900,900
| – | – |
2013 Q2
44 quarters
|
|
7
Enliven Therapeutics
ELVN
$3.25B
| $186M | 3.67% |
7,959,538
-1,038,800
| -12% | -$21.9M |
2020 Q1
17 quarters
|
|
8
Merck
MRK
$370B
| $163M | 3.22% |
1,316,000
| – | – |
2023 Q3
3 quarters
|
|
9
Tenet Healthcare
THC
$21.9B
| $156M | 3.08% |
1,173,300
| – | – |
2021 Q3
11 quarters
|
|
|
10
Janux Therapeutics
JANX
$1.06B
| $125M | 2.46% |
2,979,828
-1,295,725
| -30% | -$60.8M |
2021 Q2
12 quarters
|
|
11
Ionis Pharmaceuticals
IONS
$7.22B
| $113M | 2.23% |
2,372,333
+359,300
| +18% | +$14.7M |
2022 Q2
8 quarters
|
|
12
Sarepta Therapeutics
SRPT
$1.96B
| $102M | 2.02% |
646,000
-51,500
| -7% | -$6.62M |
2017 Q4
26 quarters
|
|
13
Stryker
SYK
$113B
| $91.5M | 1.81% |
269,000
| – | – |
2020 Q3
15 quarters
|
|
14
Elevance Health
ELV
$90.8B
| $91.1M | 1.8% |
168,100
| – | – |
2023 Q4
2 quarters
|
|
|
15
argenx
ARGX
$56.3B
| $89.9M | 1.78% |
209,100
+57,500
| +38% | +$22M |
2022 Q1
9 quarters
|
|
16
Disc Medicine
IRON
$3.56B
| $80.5M | 1.59% |
1,785,571
+83,334
| +5% | +$2.83M |
2021 Q1
13 quarters
|
|
17
ARS Pharmaceuticals
SPRY
$338M
| $78.6M | 1.55% |
9,240,887
| – | – |
2020 Q4
14 quarters
|
|
18
DELISTED
Third Harmonic Bio
THRD
| $75.1M | 1.48% |
5,779,071
| – | – |
2022 Q3
7 quarters
|
|
19
Natera
NTRA
$59.1B
| $74.4M | 1.47% |
687,500
-211,931
| -24% | -$21.5M |
2015 Q3
35 quarters
|
|
20
Thermo Fisher Scientific
TMO
$256B
| $73M | 1.44% |
132,000
| – | – |
2013 Q2
44 quarters
|
|
21
Vertex Pharmaceuticals
VRTX
$142B
| $70.8M | 1.4% |
151,000
+28,300
| +23% | +$12.3M |
2013 Q2
44 quarters
|
|
22
DELISTED
SpringWorks Therapeutics
SWTX
| $64.3M | 1.27% |
1,707,331
| – | – |
2019 Q3
19 quarters
|
|
23
Neurocrine Biosciences
NBIX
$14.9B
| $61.7M | 1.22% |
448,200
+25,100
| +6% | +$3.44M |
2018 Q1
25 quarters
|
|
|
24
Alnylam Pharmaceuticals
ALNY
$22.3B
| $60.8M | 1.2% |
+250,300
| New | +$39.5M |
2024 Q2
0 quarters
|
|
25
Vaxcyte
PCVX
$9.7B
| $60.1M | 1.19% |
795,900
-270,231
| -25% | -$18.4M |
2020 Q2
16 quarters
|
|
Similar funds
OrbiMed's Q2 2024 Portfolio in Review
As of Q2 2024, OrbiMed held 127 positions worth $5.06B, down 7.2% from $5.46B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
OrbiMed withdrew a net $277M in Q2 2024, closing 13 positions and reducing 22 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $106M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Integer Holdings worth $40.4M.
- OrbiMed's largest Q2 2024 buy was Integer Holdings: 349,221 shares worth $40.4M.
- OrbiMed added most to Exact Sciences in Q2 2024, an estimated $29.3M increase.
- OrbiMed's biggest Q2 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $104M.
- OrbiMed fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $106M.
- OrbiMed's ten largest holdings make up 44% of its $5.06B portfolio in Q2 2024.
- OrbiMed opened 13 new positions and closed 13 in Q2 2024.
- OrbiMed's portfolio value fell 7.2% quarter-over-quarter to $5.06B.
Based on OrbiMed's 13F filing for Q2 2024, filed 14 Aug 2024.